2021 annual financial data
Spyre Therapeutics 2021 Operating margin
Direct answer
Operating margin was -350.33%.
Operating income was -65,649,000 USD and net income was -65,801,000 USD.
Operating cash flow was -53,716,000 USD.
Get free Spyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 18,739,000 USD
- Operating income
- -65,649,000 USD
- Net income
- -65,801,000 USD
- Operating cash flow
- -53,716,000 USD